13F HOLDINGS REPORT
GILEAD SCIENCES, INC.
Quarter ended Q3 2025 · Filed November 13, 2025 · Accession 0001123292-25-000642
Total Value
$1.79B
Positions
9
Other Managers
1
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | GALAPAGOS NV | GLPGF | 16,707,477 | $578.7M | 32.31% |
| 2 | ARCELLX INC | ACLX | 6,720,803 | $551.8M | 30.80% |
| 3 | ARCUS BIOSCIENCES INC | RCUS | 31,424,760 | $427.4M | 23.86% |
| 4 | ASSEMBLY BIOSCIENCES INC | ASMB | 4,505,391 | $115.3M | 6.44% |
| 5 | MERUS N V | N5749R100 | 452,527 | $42.6M | 2.38% |
| 6 | TANGO THERAPEUTICS INC | TNGX | 4,854,443 | $40.8M | 2.28% |
| 7 | KYVERNA THERAPEUTICS INC | KYTX | 4,126,119 | $24.8M | 1.38% |
| 8 | XILIO THERAPEUTICS INC | XLO | 9,105,451 | $7.7M | 0.43% |
| 9 | LEAP THERAPEUTICS INC | CYPH | 5,319,148 | $2.4M | 0.13% |